Research programme: gastrointestinal disorder therapeutics - NeurogastrxAlternative Names: NG 101
Latest Information Update: 05 Nov 2015
At a glance
- Originator Neurogastrx
- Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists; Dopamine receptor modulators; Serotonin receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Gastroparesis
- Research Gastrointestinal disorders
Most Recent Events
- 03 Nov 2015 Preclinical trials in Gastroparesis in USA (unspecified route)